InDex Pharmaceuticals discontinues cobitolimod phase III program

/PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announces that an independent DMC has completed the planned dose...

Related Keywords

Sweden ,Stockholm ,Swedish ,Jenny Sundqvist ,Johan Gil ,Prnewswire Index Pharmaceuticals Holding ,Data Monitoring Committee ,Kindex Pharmaceuticals ,Index Pharmaceuticals Holding ,Independent Data Monitoring Committee ,Induction Study ,Abuse Regulation ,Dex Pharmaceuticals ,Nasdaq First North Growth Market ,